X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-10-17 | ARTV | Artiva Biotherapeutics, Inc. | Aslan Fred | Pres, CEO | S - Sale | $6.00 | -25,500 | 356,721 | -7% | -$153,000 | ||||||
2025-10-17 | LXEO | Lexeo Therapeutics, Inc. | See Tai Sandi | Chief Development Officer | S - Sale | $8.94 | -3,888 | 65,862 | -6% | -$34,767 | ||||||
2025-10-17 | LXEO | Lexeo Therapeutics, Inc. | Robertson Jenny | GC | S - Sale | $8.94 | -3,526 | 68,930 | -5% | -$31,530 | ||||||
2025-10-17 | LXEO | Lexeo Therapeutics, Inc. | Otero Jose Manuel | Chief Technical Officer | S - Sale | $8.94 | -2,115 | 64,197 | -3% | -$18,913 | ||||||
2025-10-17 | LXEO | Lexeo Therapeutics, Inc. | Adler Eric | Chief Medical Officer | S - Sale | $8.94 | -3,382 | 73,261 | -4% | -$30,242 | ||||||
2025-10-17 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | CEO | S - Sale | $8.94 | -13,133 | 242,118 | -5% | -$117,436 | ||||||
| M | 2025-10-15 | VOR | Vor Biopharma Inc. | Reprogrammed Interchange LLC | 10% | S - Sale | $31.88 | -73,676 | 1,204,442 | -6% | -$2,348,744 | |||||
| M | 2025-10-15 | VOR | Vor Biopharma Inc. | Ra Capital Management, L.P. | Dir, 10% | S - Sale | $29.54 | -464,025 | 15,104 | -97% | -$13,707,361 | |||||
| M | 2025-10-15 | VIR | Vir Biotechnology, Inc. | Svf Endurance (Cayman) Ltd | 10% | S - Sale | $6.08 | -29,515 | 15,340,494 | 0% | -$179,563 | |||||
2025-10-15 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $118.08 | -2,500 | 157,055 | -2% | -$295,200 | ||||||
2025-10-15 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Commercial Officer | S - Sale | $118.08 | -3,000 | 110,193 | -3% | -$354,240 | ||||||
2025-10-16 | AURA | Aura Biosciences, Inc. | Plavsic Mark | CTO | S - Sale | $6.35 | -12,169 | 197,287 | -6% | -$77,273 | ||||||
2025-10-15 | STRO | Sutro Biopharma, Inc. | Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER | P - Purchase | $0.80 | +17,000 | 71,832 | +31% | +$13,607 | ||||||
2025-10-15 | STRO | Sutro Biopharma, Inc. | Chow Gregory K. | CFO | P - Purchase | $0.81 | +19,750 | 19,750 | New | +$15,998 | ||||||
2025-10-15 | STRO | Sutro Biopharma, Inc. | Chung Jane | CEO | P - Purchase | $0.80 | +12,500 | 122,850 | +11% | +$10,011 | ||||||
2025-10-15 | STRO | Sutro Biopharma, Inc. | Matsui Connie | Dir | P - Purchase | $0.80 | +50,000 | 50,000 | New | +$39,950 | ||||||
2025-10-15 | STRO | Sutro Biopharma, Inc. | Pauling David | Chief Admin. Ofcr., GC | P - Purchase | $0.80 | +12,504 | 71,737 | +21% | +$9,993 | ||||||
2025-10-15 | ACLX | Arcellx, Inc. | Gilson Michelle | CFO | S - Sale | $91.04 | -5,364 | 8,466 | -39% | -$488,315 | ||||||
| M | 2025-10-10 | VOR | Vor Biopharma Inc. | Reprogrammed Interchange LLC | 10% | S - Sale | $31.08 | -96,657 | 1,278,118 | -7% | -$3,003,706 | |||||
| D | 2025-10-14 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale+OE | $66.60 | -4,242 | 290,758 | -1% | -$282,517 | |||||
| D | 2025-10-14 | CRSP | Crispr Therapeutics AG | Kasinger James R. | GC, Secretary | S - Sale+OE | $66.60 | -1,076 | 83,402 | -1% | -$71,662 | |||||
| D | 2025-10-15 | KYMR | Kymera Therapeutics, Inc. | Gollob Jared | Chief Medical Officer | S - Sale+OE | $61.42 | -59,576 | 109,992 | -35% | -$3,659,254 | |||||
| D | 2025-10-13 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale+OE | $48.54 | -25,000 | 284,047 | -8% | -$1,213,540 | |||||
| D | 2025-10-13 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $43.25 | -1,000 | 0 | -100% | -$43,250 | |||||
2025-10-10 | ZIVO | Zivo Bioscience, Inc. | Yaldoo Laith L | Dir, 10% | P - Purchase | $12.05 | +1,659 | 575,095 | 0% | +$19,991 | ||||||
| D | 2025-10-13 | KYMR | Kymera Therapeutics, Inc. | Gollob Jared | Chief Medical Officer | S - Sale+OE | $60.00 | -3,114 | 118,359 | -3% | -$186,840 | |||||
| M | 2025-10-09 | VIR | Vir Biotechnology, Inc. | Svf Endurance (Cayman) Ltd | 10% | S - Sale | $6.14 | -251,360 | 15,370,009 | -2% | -$1,543,899 | |||||
| D | 2025-10-10 | FENC | Fennec Pharmaceuticals Inc. | Rallis Chris A | Dir | S - Sale+OE | $9.24 | -1,775 | 57,079 | -3% | -$16,401 | |||||
2025-10-09 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale | $10.00 | -2,408 | 5,188 | -32% | -$24,080 | ||||||
| D | 2025-10-13 | KYMR | Kymera Therapeutics, Inc. | Albers Jeffrey W. | Dir | S - Sale+OE | $59.19 | -5,000 | 0 | -100% | -$295,949 | |||||
| M | 2025-10-08 | CGEM | Cullinan Therapeutics, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $6.73 | +1,459,641 | 16,194,827 | +10% | +$9,826,941 | |||||
2025-10-09 | RGNX | Regenxbio Inc. | Simpson Curran | CEO | S - Sale | $12.62 | -20,811 | 216,162 | -9% | -$262,635 | ||||||
| D | 2025-10-10 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $6.04 | -100,000 | 954,229 | -9% | -$604,000 | |||||
| M | 2025-10-08 | VOR | Vor Biopharma Inc. | Reprogrammed Interchange LLC | 10% | S - Sale | $33.16 | -124,146 | 1,374,775 | -8% | -$4,116,369 | |||||
| D | 2025-10-09 | CGON | Cg Oncology, Inc. | Mulay James | Dir | S - Sale+OE | $43.99 | -5,903 | 0 | -100% | -$259,673 | |||||
| M | 2025-10-08 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $31.96 | -5,517 | 91,525 | -6% | -$176,315 | |||||
2025-10-08 | IMVT | Immunovant, Inc. | Geffner Michael | Chief Medical Officer | S - Sale | $16.30 | -1,272 | 220,553 | -1% | -$20,734 | ||||||
2025-10-08 | IMVT | Immunovant, Inc. | Stout Jay S | CTO | S - Sale | $16.30 | -1,585 | 203,334 | -1% | -$25,836 | ||||||
| M | 2025-10-08 | ATYR | Atyr Pharma Inc | Schimmel Paul | Dir | P - Purchase | $0.91 | +1,000,000 | 2,101,056 | +91% | +$911,801 | |||||
| M | 2025-10-07 | FENC | Fennec Pharmaceuticals Inc. | Southpoint Capital Advisors LP | 10% | S - Sale | $9.48 | -67,114 | 4,010,100 | -2% | -$636,229 | |||||
2025-10-07 | INBX | Inhibrx Biosciences, Inc. | Viking Global Investors LP | 10% | S - Sale | $32.25 | -350,000 | 102,864 | -77% | -$11,287,500 | ||||||
| M | 2025-10-07 | VIR | Vir Biotechnology, Inc. | Svf Endurance (Cayman) Ltd | 10% | S - Sale | $5.99 | -538,375 | 15,621,369 | -3% | -$3,223,939 | |||||
2025-10-08 | ZIVO | Zivo Bioscience, Inc. | Maggiore Christopher D. | Dir, 10% | P - Purchase | $12.01 | +23,682 | 517,526 | +5% | +$284,421 | ||||||
| M | 2025-10-06 | VOR | Vor Biopharma Inc. | Reprogrammed Interchange LLC | 10% | S - Sale | $36.12 | -98,387 | 1,498,921 | -6% | -$3,553,499 | |||||
2025-10-06 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $32.19 | -5,875 | 97,042 | -6% | -$189,099 | ||||||
| D | 2025-10-06 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $32.19 | -31,348 | 601,212 | -5% | -$1,008,998 | |||||
2025-10-06 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $32.19 | -2,041 | 46,413 | -4% | -$65,694 | ||||||
2025-10-06 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $32.19 | -9,724 | 114,678 | -8% | -$312,986 | ||||||
2025-10-06 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $32.19 | -23,747 | 208,735 | -10% | -$764,345 | ||||||
2025-10-06 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $32.19 | -3,876 | 98,710 | -4% | -$124,757 | ||||||
2025-10-07 | MGTX | Meiragtx Holdings Plc | Forbes Alexandria | Pres, CEO | S - Sale | $8.39 | -47,500 | 1,313,983 | -3% | -$398,525 | ||||||
| M | 2025-10-03 | SRRK | Scholar Rock Holding Corp | Akkaraju Srinivas | Dir | P - Purchase | $37.58 | +500,439 | 5,824,381 | +9% | +$18,807,352 | |||||
2025-10-03 | VYGR | Voyager Therapeutics, Inc. | Jorgensen Nathan D. | CFO | S - Sale | $4.78 | -7,666 | 123,834 | -6% | -$36,643 | ||||||
| M | 2025-10-03 | VIR | Vir Biotechnology, Inc. | Svf Endurance (Cayman) Ltd | 10% | S - Sale | $5.57 | -524,297 | 16,159,744 | -3% | -$2,922,426 | |||||
| M | 2025-10-03 | ACLX | Arcellx, Inc. | Gilson Michelle | CFO | S - Sale | $86.04 | -5,946 | 13,830 | -30% | -$511,603 | |||||
2025-10-06 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale | $9.78 | -10,000 | 82,501 | -11% | -$97,800 | ||||||
2025-10-02 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $29.16 | -124 | 102,586 | 0% | -$3,616 | ||||||
2025-10-02 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $29.16 | -140 | 124,402 | 0% | -$4,083 | ||||||
| D | 2025-10-02 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $29.16 | -476 | 632,560 | 0% | -$13,881 | |||||
2025-10-02 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $29.16 | -206 | 232,482 | 0% | -$6,007 | ||||||
| M | 2025-10-01 | VOR | Vor Biopharma Inc. | Reprogrammed Interchange LLC | 10% | S - Sale | $39.43 | -41,752 | 1,597,308 | -3% | -$1,646,237 | |||||
| D | 2025-10-01 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale+OE | $39.80 | -5,110 | 284,733 | -2% | -$203,378 | |||||
| DM | 2025-10-01 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $71.86 | -60,000 | 733,719 | -8% | -$4,311,745 | |||||
2025-10-01 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale | $15.00 | -5,609 | 5,503 | -50% | -$84,135 | ||||||
| D | 2025-08-08 | ASMB | Assembly Biosciences, Inc. | Gilead Sciences, Inc. | 10% | P - Purchase | $0.00 | +2,295,920 | 4,505,391 | +104% | +$0 | |||||
2025-10-01 | BEAM | Beam Therapeutics Inc. | Cavanagh Bethany J | SVP, Finance, Treasurer | S - Sale | $24.53 | -467 | 44,045 | -1% | -$11,456 | ||||||
2025-10-01 | BEAM | Beam Therapeutics Inc. | Bellon Christine | GC | S - Sale | $24.53 | -373 | 116,921 | 0% | -$9,150 | ||||||
| DM | 2025-10-01 | BEAM | Beam Therapeutics Inc. | Evans John M. | CEO | S - Sale+OE | $24.57 | -50,000 | 1,089,667 | -4% | -$1,228,323 | |||||
2025-09-30 | ZIVO | Zivo Bioscience, Inc. | Yaldoo Laith L | Dir, 10% | P - Purchase | $15.99 | +15,322 | 573,436 | +3% | +$244,999 | ||||||
2025-09-30 | LENZ | Lenz Therapeutics, Inc. | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $46.01 | -224,974 | 2,656,888 | -8% | -$10,352,017 | ||||||
| D | 2025-09-30 | IMCR | Immunocore Holdings Plc | Berman David M | HEAD OF R, D | S - Sale+OE | $35.23 | -61,849 | 0 | -100% | -$2,178,940 | |||||
2025-10-01 | VIR | Vir Biotechnology, Inc. | Sato Vicki L | Dir | S - Sale | $5.84 | -22,000 | 1,232,391 | -2% | -$128,396 | ||||||
2025-10-01 | HALO | Halozyme Therapeutics, Inc. | Connaughton Bernadette | Dir | S - Sale | $75.24 | -2,000 | 44,952 | -4% | -$150,481 | ||||||
| D | 2025-09-30 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $40.09 | -5,000 | 0 | -100% | -$200,450 | |||||
2025-09-29 | RGNX | Regenxbio Inc. | Simpson Curran | CEO | S - Sale | $10.03 | -7,624 | 236,973 | -3% | -$76,469 | ||||||
2025-09-30 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale | $81.28 | -21,034 | 624 | -97% | -$1,709,723 | ||||||
2025-09-29 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $111.66 | -10,000 | 591,203 | -2% | -$1,116,564 | ||||||
| D | 2025-09-29 | CGON | Cg Oncology, Inc. | Mulay James | Dir | S - Sale+OE | $39.19 | -12,755 | 0 | -100% | -$499,868 | |||||
2025-09-26 | DTIL | Precision Biosciences Inc | Frankel Stanley | Dir | P - Purchase | $4.97 | +2,700 | 16,778 | +19% | +$13,419 | ||||||
2025-09-29 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale | $80.16 | -73 | 21,658 | 0% | -$5,852 | ||||||
2025-09-23 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale | $8.00 | -2,407 | 7,596 | -24% | -$19,256 | ||||||
2025-09-26 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale | $80.12 | -12,396 | 21,731 | -36% | -$993,155 | ||||||
| D | 2025-09-25 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $4.76 | -100,000 | 954,229 | -9% | -$476,000 | |||||
2025-09-24 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale | $44.26 | -1,799 | 50,425 | -3% | -$79,624 | ||||||
2025-09-24 | TARS | Tarsus Pharmaceuticals, Inc. | Azamian Bobak R. | Pres, CEO, Board Chair | S - Sale | $55.37 | -6,000 | 865,741 | -1% | -$332,220 | ||||||
2025-09-23 | SMNR | Semnur Pharmaceuticals, Inc. | Scilex Holding Co | 10% | S - Sale | $16.00 | -12,500,000 | 188,554,849 | -6% | -$200,000,000 | ||||||
2025-09-22 | SRRK | Scholar Rock Holding Corp | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | S - Sale | $30.67 | -3,353 | 108,964 | -3% | -$102,846 | ||||||
2025-09-22 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $27.56 | -233 | 102,710 | 0% | -$6,421 | ||||||
2025-09-22 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $27.56 | -295 | 124,542 | 0% | -$8,130 | ||||||
| D | 2025-09-22 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $27.56 | -1,704 | 633,036 | 0% | -$46,962 | |||||
| D | 2025-09-22 | JSPR | Jasper Therapeutics, Inc. | Wiggans Thomas G | Dir | P - Purchase | $2.43 | +41,000 | 46,000 | +820% | +$99,630 | |||||
| D | 2025-09-22 | JSPR | Jasper Therapeutics, Inc. | Lucas Svetlana | Dir | P - Purchase | $2.43 | +20,000 | 20,000 | New | +$48,600 | |||||
| D | 2025-09-22 | JSPR | Jasper Therapeutics, Inc. | Martell Ron | Pres, CEO | P - Purchase | $2.43 | +41,000 | 74,118 | +124% | +$99,630 | |||||
| D | 2025-09-22 | JSPR | Jasper Therapeutics, Inc. | Shizuru Judith Anne | Dir | P - Purchase | $2.43 | +41,000 | 156,901 | +35% | +$99,630 | |||||
2025-09-22 | DTIL | Precision Biosciences Inc | Brown Melinda | Dir | P - Purchase | $4.89 | +1,400 | 21,965 | +7% | +$6,846 | ||||||
2025-09-22 | HALO | Halozyme Therapeutics, Inc. | Labrosse Nicole | SVP, CFO | S - Sale | $77.95 | -2,227 | 22,079 | -9% | -$173,584 | ||||||
| D | 2025-09-19 | BCDA | Biocardia, Inc. | Stertzer Simon H | Dir | P - Purchase | $1.25 | +398,400 | 714,275 | +126% | +$498,000 | |||||
| D | 2025-09-19 | BCDA | Biocardia, Inc. | Blank Andrew Scott | Dir | P - Purchase | $1.25 | +288,000 | 636,058 | +83% | +$360,000 | |||||
| D | 2025-09-19 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.25 | +48,000 | 216,762 | +28% | +$60,000 | |||||
2025-09-18 | LENZ | Lenz Therapeutics, Inc. | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $42.23 | -135,304 | 2,881,862 | -4% | -$5,714,356 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |